IN THE 2000S, DIGITAL PATHOLOGY WAS THE HOT NEW TECHNOLOGY that held great potential to transform anatomic pathology in myriad ways, not the least of which was an essential tool to streamline pathologist workflow while supporting greater diagnostic precision.
Yet today, approximately 10 years later, those high hopes for the digital pathology market have not come
CEO SUMMARY: There’s a new competitor in the digital pathology marketplace with ambitious plans to deliver a fully-integrated pathologist workflow solution. Inspirata, Inc., of Tampa, Florida, made its debut in March at an international pathology conference. In this exclusive interview, Inspirata Chairman and CEO Satish K. Sanan explains his company’s strategic vision for digital pathology, along with the details of how Inspirata intends to overcome digital pathology’s return-on-investment challenge.
Big news last week was the unanimous decision by the Supreme Court that natural genes cannot be patented. The case was brought against Myriad Genetics, Inc., by the American Civil Liberties Union, the Association for Molecular Pathology, and several other plaintiffs. The decision invalidated some of the patents held by Myriad for the BRCA 1
SIEMENS INVESTS IN DIGITAL PATHOLOGY, BUYS STAKE IN BIOIMAGENE
IMAGING AND RADIOLOGY GIANT SIEMENS just made an interesting investment in digital pathology systems. On October 16, Siemens Venture Capital (SVC) revealed that it had purchased a stake in BioImagene Inc. (www.bioimagene.com) of Cupertino, California. The amount of the investment was not disclosed.
CEO SUMMARY: If BioImagene’s CEO is to be believed, the company is ready to deliver a digital pathology system that is robust and affordable, even in settings with just two or three pathologists. One key to the BioImagene strategy is “per scan” pricing that avoids the need for upfront capital to acquire its system. Confident
CEO SUMMARY: Digital pathology imaging systems are finding uses in all phases of drug discovery (discovery, pre-clinical, clinical trials), as well as education, research, and clinical. One hurdle to widespread adoption of fully digitized, whole-slide pathology imaging systems is FDA clearance that allows the use of this technology for primary diagnosis. Executives at two of